Both Wegovy and Tirzepatide are innovative medications designed people address obesity, but they function through distinct mechanisms. Semaglutide primarily targets glucagon-like peptide-1 (GLP-1) receptors, encouraging insulin release and diminishing appetite . Mounjaro, conversely , is a double agonist that affects both GLP-1 receptors and GIP, m